Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Jaguar Animal Health ( (JAGX) ) is now available.
On May 6, 2026, Jaguar Health received a decision from a Nasdaq Hearings Panel granting a short extension to regain compliance with Nasdaq’s listing rules, following a May 1, 2026 notice that it had fallen below the required 500,000 publicly held shares and the $1.00 minimum bid price. After certain third-party investors exercised pre-funded warrants on May 4, 2026, the company cured the publicly held shares deficiency, resetting the compliance period for the $1.00 bid price rule and extending the deadline to achieve at least 10 consecutive trading days at or above that level from May 15, 2026 to May 18, 2026, while warning that failure to do so could result in delisting from Nasdaq.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
The score is weighed down primarily by weak financial quality (large losses, negative equity, high leverage) and very bearish technicals (far below moving averages with negative MACD). Corporate actions to address financing and Nasdaq compliance provide some support, but valuation offers limited help given ongoing losses and no dividend data.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Jaguar Health, Inc. is a pharmaceutical company listed on the Nasdaq Capital Market. The company focuses on developing and commercializing medicines, with its stock subject to Nasdaq’s continued listing requirements, including minimum bid price and publicly held share thresholds that are critical for maintaining its exchange listing.
Average Trading Volume: 33,479
Technical Sentiment Signal: Sell
Current Market Cap: $1.13M
See more data about JAGX stock on TipRanks’ Stock Analysis page.